Themed data sheets


Infoday presentation ERA PerMed Joint Transnational Call 2022: Prevention in Personalised Medicine


This time we focus on the event "Infoday presentation ERA PerMed JTC2022: Prevention in Personalised Medicine", organised by ERA PerMed on 09 December 2021.


Access to financing

General information

The ERA PerMed is a partnership co-funded by 32 partners from 23 countries and the European Commission (EC), which aims to align national research strategies, promote excellence, strengthen the competitiveness of European actors in Personalised Medicine (PM), and improve European collaboration with countries outside the EU. To this end, 33 funding organisations, including Navarra, have agreed to launch the fifth Transnational Joint Call (not co-funded by the EC) for innovative collaborative research projects in Personalised Medicine. The budget available for this call is 29 million euros (approximately). The general objectives of the ERA PerMed call are:

  • Support translational research projects in the field of personalised medicine;
  • Encourage and enable interdisciplinary collaborations for the implementation of Personalised Medicine, combining pre-clinical or clinical research with bioinformatics components, as well as ELSA research or application research, including health economics;
  • Foster collaboration between academia (research teams from universities, higher education institutions, public research institutions, research centres), clinical/healthcare research (research teams from hospitals/public health, healthcare facilities and other healthcare organisations), private partners, e.g. SMEs (small and medium-sized enterprises), as well as policymakers, regulatory agencies and patient organisations.

Objectives of the 2022 call

With its fifth transnational call, ERA PerMed aims to foster prevention research in personalised medicine. The overall objective of the call is to develop tailor-made strategies for disease prevention and disease progression at three different levels:

  • Preventive measures to decrease the incidence rate (primary prevention);
  • Early detection to increase the effectiveness of preventive therapy, even before symptoms develop (secondary prevention);
  • Interventions that prevent disease recurrence or improve patient care and quality of life (tertiary prevention).
  • Research on the prevention of over-treatment or over-medicalisation in primary, secondary and tertiary personalised preventive approaches is optional and could be part of research proposals, if appropriate.
  • research proposals, if appropriate. The clinical relevance of the proposed personalised prevention approach needs to be convincingly demonstrated.

Scope of the call
The call is articulated around three research areas, in order to ensure the development of specific approaches to personalised medicine taking into account the main aspects necessary for its successful implementation in health systems: (1) Translating basic research to clinical research and beyond, (2) Data and Information and Communication Technologies (ICT) and (3) Responsible and effective implementation in healthcare.

The aspects to be taken into account for the formation of the consortium are:

  1. The project partners must belong to one of the eligible categories (Academia; Public clinical/health sector; and Private for-profit or not-for-profit sector), with the inclusion of partners from the different categories always highly recommended. The consortium must be formed by at least 3 partners eligible for funding, from 3 different countries participating in the call.
  2. At least two of the partners must be from two different Member States or associated countries.
  3. The maximum number of partners per pre-proposal is 6, and no more than two partners from the same country will be accepted in the same consortium (including self-funded partners). At full proposal stage, the consortium can be increased up to 7 partners in total, only with the inclusion of one partner from an under-represented country (a list of under-represented countries will be provided to coordinators invited to submit full proposals).
  4. No more than one self-funded partner is allowed in consortia with at least three partners eligible for funding.
  5. It is mandatory to integrate at least one early stage researcher as principal investigator in the consortium.
  6. The consortium must be international, interdisciplinary and cross-sectoral.
  7. The inclusion of end-users in the project (patient organisations, health centres, etc.) is highly recommended.
  8. It is strongly recommended that sex and gender considerations, as well as under-represented populations (e.g. ethnic minorities), or under-represented patient subgroups (e.g. children, elderly) are taken into account in both the proposal and the research teams.

Note: For more information on eligibility requirements, it is essential to review the official call documents.

Finally, please note that the IC PerMed platform that allows you to search for partners and present your expertise to the personalised medicine research community is available: ICPerMed Partnering Tool.

Back to list